StockData

TScan Therapeutics vs Taysha Gene Therapies

TCRX and TSHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How TCRX and TSHA compare

Taysha Gene Therapies is the larger company, worth 127 times as much as TScan Therapeutics ($1.3B against $10.2M).

TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −32.3% for Taysha Gene Therapies).

TScan Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1655% compared with −2728% at Taysha Gene Therapies.

Taysha Gene Therapies scores higher on the StockData Score (5 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricTCRXTSHA
Size and price
Market cap$10.2M$1.3B
Share price$0.151$4.00
Change, 1 year−86.3%−3.1%
Change, 5 years−98.3%−68.5%
Beta (5Y)2.152.80
Employees14299
StockData Score
Total score45 (better)
Valuation score3 (better)0
Growth score01 (better)
Performance score01 (better)
Health score13 (better)
Dividend score00
Valuation
P/S1.4× (better)238×
P/B0.1× (better)3.4×
FCF yield−1157%−10.2% (better)
Fair value$1.36–
Margin of safety88.9%–
Growth
Revenue growth (TTM)2.2% (better)−32.3%
Revenue growth, 5Y average56.9%–
Profitability
Operating margin−1695% (better)−2792%
Net margin−1655% (better)−2728%
FCF margin−1666% (better)−2417%
Return on equity−95.8%−47.1% (better)
Financial health
Debt / equity0.470.13 (better)
Interest coverage−43.2× (better)−3646.6×
Current ratio3.3717.76 (better)
Altman Z-score−6.317.07 (better)
Piotroski F-score25 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions53.5%91.9%
Held by insiders32.8%10.7%
Insider net buying, 12 months$146K (better)−$6.1M
Short interest, % of float4.4%18.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.